Romy A. M. Klein Kranenbarg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Romy A. M. Klein Kranenbarg has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Beatrijs Wokke
Department of Neurology, MS Centre ErasMS, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
3 shared publicationsJanet de Beukelaar
Department of Neurology, Albert Schweitzer Hospital, Dordrecht, The Netherlands
3 shared publications- Fabiënne van Puijfelik
Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; MS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, the Netherlands
2 shared publications Jasper Rip
Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; MS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, the Netherlands
2 shared publicationsJoost Smolders
Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; MS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; Neuroimmunology Research Group, Netherlands Institute for Neuroscience, Amsterdam, the Netherlands
2 shared publications- Joost Smolders
Department of Immunology, MS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 6 June 2026
- Published by Elsevier in EBioMedicine
- Vol. 129, 106324
Refined single-cell profiling captures a CCR5high CD4+ cytotoxic T-cell precursor in multiple sclerosis
- 6 June 2026
- Published by Elsevier in EBioMedicine
- Vol. 129, 106324
Open AccessRefined single-cell profiling captures a CCR5high CD4+ cytotoxic T-cell precursor in multiple sclerosis
- Open Access
- 5 March 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (3) , 182
Symptoms of depression and anxiety are early predictors of multi-domain disability progression in progressive MS
Introduction In multiple sclerosis (MS), depression and anxiety are common, yet their relation to disease progression is unclear. We investigated whether Hospital Anxiety and Depression Scale (HADS) symptoms predict neurological disability progression. Methods In our prospective cohort of people with primary progressive MS (PPMS), depressive and anxiety symptoms were assessed using HADS. Disability progression at 1 and 2 years was assessed using three predefined endpoints: (1) Expanded Disability Status Scale (EDSS), (2) a three-variable composite endpoint (EDSS, Timed 25-Foot Walk (T25FW), or Arm Function in Multiple Sclerosis Questionnaire (AMSQ)), and (3) a five-variable composite endpoint (EDSS, T25FW, AMSQ, Symbol Digit Modalities Test (SDMT), or Patient-Determined Disease Steps (PDDS)). Logistic regression modelled whether HADS scores predicted disability progression. Boruta feature selection identified the most informative HADS items. Results One hundred eleven adults with PPMS completed the HADS (all ≥ 1-year follow-up; 62 ≥ 2 years). Progression occurred predominantly on individual domains. At 1 year, higher total HADS scores predicted progression on the five-variable composite endpoint (OR 3.10, [95% CI 0.99–9.75], p = 0.05; AUC 0.59, [95% CI 0.47–0.70]). At 2 years, the depression sub-score consistently predicted progression on EDSS (OR 8.88, [95% CI 1.12–70.66], p = 0.04), and the five-variable composite endpoint (OR 9.46, [95% CI 1.50–59.52], p = 0.02). Boruta feature selection identified HADS depression-associated items 6 and 8 as best predictors; together achieving similar predictive accuracy compared to the full HADS questionnaire. Conclusion Higher HADS scores, particularly depressive symptoms, predicted disability progression. These findings indicate prognostic value of patient-reported outcomes in predicting disease worsening and their potential use in guiding personalised treatment in progressive MS.
- 5 March 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (3) , 182
Open AccessSymptoms of depression and anxiety are early predictors of multi-domain disability progression in progressive MS
Introduction In multiple sclerosis (MS), depression and anxiety are common, yet their relation to disease progression is unclear. We investigated whether Hospital Anxiety and Depression Scale (HADS) symptoms predict neurological disability progression. Methods In our prospective cohort of people with primary progressive MS (PPMS), depressive and anxiety symptoms were assessed using HADS. Disability progression at 1 and 2 years was assessed using three predefined endpoints: (1) Expanded Disability Status Scale (EDSS), (2) a three-variable composite endpoint (EDSS, Timed 25-Foot Walk (T25FW), or Arm Function in Multiple Sclerosis Questionnaire (AMSQ)), and (3) a five-variable composite endpoint (EDSS, T25FW, AMSQ, Symbol Digit Modalities Test (SDMT), or Patient-Determined Disease Steps (PDDS)). Logistic regression modelled whether HADS scores predicted disability progression. Boruta feature selection identified the most informative HADS items. Results One hundred eleven adults with PPMS completed the HADS (all ≥ 1-year follow-up; 62 ≥ 2 years). Progression occurred predominantly on individual domains. At 1 year, higher total HADS scores predicted progression on the five-variable composite endpoint (OR 3.10, [95% CI 0.99–9.75], p = 0.05; AUC 0.59, [95% CI 0.47–0.70]). At 2 years, the depression sub-score consistently predicted progression on EDSS (OR 8.88, [95% CI 1.12–70.66], p = 0.04), and the five-variable composite endpoint (OR 9.46, [95% CI 1.50–59.52], p = 0.02). Boruta feature selection identified HADS depression-associated items 6 and 8 as best predictors; together achieving similar predictive accuracy compared to the full HADS questionnaire. Conclusion Higher HADS scores, particularly depressive symptoms, predicted disability progression. These findings indicate prognostic value of patient-reported outcomes in predicting disease worsening and their potential use in guiding personalised treatment in progressive MS.
- Open Access
- 5 February 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (2) , e70052
Multifaceted Biomarkers Suggest a Similar Profile of CNS Pathology in Relapsing and Progressive MS
Background: Relapsing–remitting (RR) and primary progressive (PP) multiple sclerosis (MS) have distinct clinical courses, but underlying pathophysiological differences remain unclear. We compared pathological components between RRMS, PPMS, and other inflammatory and neurodegenerative disorders, leveraging soluble biomarkers and post‐mortem pathology.Methods: Serum and cerebrospinal fluid (CSF) of people diagnosed with (pw) PPMS (n = 104), RRMS (n = 38), Alzheimer's disease (AD, n = 22), neuromyelitis optica spectrum disorder (NMOSD, n = 10), and myelin oligodendrocyte glycoprotein–associated disease (MOGAD, n = 10) were collected. B‐cell maturation antigen (BCMA), soluble CD27 (sCD27), osteopontin (OPN), chitinase‐3‐like‐1 (CHI3L1), glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL) and synaptosomal‐associated protein‐25 (SNAP25) were measured. Lymphocytes (CD20+, CD138+, CD3+) and pyramidal‐tract axonal density in RR‐onset (n = 86) and PPMS (n = 45) post‐mortem brain tissue were quantified.Results: Soluble and post‐mortem tissue biomarkers did not differ between pwRRMS and pwPPMS. Compared to AD, MS had higher CSF sCD27 (p < 0.001) but lower serum CHI3L1 and GFAP, and CSF OPN and SNAP25 (all p < 0.05). Serum OPN was lower in RRMS than NMOSD (p = 0.013). Principal component analyses and K‐means clustering showed substantial overlap of RRMS and PPMS biomarkers, distinct from AD. In all pwMS, serum NfL and CSF BCMA correlated with clinical/radiological disease activity, CSF BCMA and sCD27 with inflammatory parameters, and serum GFAP, CSF GFAP, and CSF NfL with Expanded Disability Status Scale (EDSS) score.Conclusions: Serum and CSF soluble biomarker profiles and post‐mortem pathology do not differentiate RRMS from PPMS diagnoses but reflect the extent of inflammation and tissue damage. Detailed assessment of MS‐associated inflammation and tissue damage may enhance classification and therapeutic strategies.
- 5 February 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (2) , e70052
Open AccessMultifaceted Biomarkers Suggest a Similar Profile of CNS Pathology in Relapsing and Progressive MS
Background: Relapsing–remitting (RR) and primary progressive (PP) multiple sclerosis (MS) have distinct clinical courses, but underlying pathophysiological differences remain unclear. We compared pathological components between RRMS, PPMS, and other inflammatory and neurodegenerative disorders, leveraging soluble biomarkers and post‐mortem pathology.Methods: Serum and cerebrospinal fluid (CSF) of people diagnosed with (pw) PPMS (n = 104), RRMS (n = 38), Alzheimer's disease (AD, n = 22), neuromyelitis optica spectrum disorder (NMOSD, n = 10), and myelin oligodendrocyte glycoprotein–associated disease (MOGAD, n = 10) were collected. B‐cell maturation antigen (BCMA), soluble CD27 (sCD27), osteopontin (OPN), chitinase‐3‐like‐1 (CHI3L1), glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL) and synaptosomal‐associated protein‐25 (SNAP25) were measured. Lymphocytes (CD20+, CD138+, CD3+) and pyramidal‐tract axonal density in RR‐onset (n = 86) and PPMS (n = 45) post‐mortem brain tissue were quantified.Results: Soluble and post‐mortem tissue biomarkers did not differ between pwRRMS and pwPPMS. Compared to AD, MS had higher CSF sCD27 (p < 0.001) but lower serum CHI3L1 and GFAP, and CSF OPN and SNAP25 (all p < 0.05). Serum OPN was lower in RRMS than NMOSD (p = 0.013). Principal component analyses and K‐means clustering showed substantial overlap of RRMS and PPMS biomarkers, distinct from AD. In all pwMS, serum NfL and CSF BCMA correlated with clinical/radiological disease activity, CSF BCMA and sCD27 with inflammatory parameters, and serum GFAP, CSF GFAP, and CSF NfL with Expanded Disability Status Scale (EDSS) score.Conclusions: Serum and CSF soluble biomarker profiles and post‐mortem pathology do not differentiate RRMS from PPMS diagnoses but reflect the extent of inflammation and tissue damage. Detailed assessment of MS‐associated inflammation and tissue damage may enhance classification and therapeutic strategies.
- Open Access
- 28 December 2023
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 6 (1) , fcae021
Ocrelizumab associates with reduced cerebrospinal fluid B and CD20dim CD4+ T cells in primary progressive multiple sclerosis
The anti-CD20 monoclonal antibody ocrelizumab reduces disability progression in primary progressive multiple sclerosis. CD20 is a prototypical B cell marker, however subpopulations of CD4+ and CD8+ T cells in peripheral blood and cerebrospinal fluid (CSF) also express low levels of CD20 (CD20dim). Therefore, direct targeting and depletion of these CD20dim T-cell-subpopulations may contribute to the therapeutic effect of ocrelizumab. The aim of this observational cohort study was to compare CD20+ B cell and CD20dim T cell distributions between peripheral blood and CSF of ocrelizumab-treated or untreated people with primary progressive multiple sclerosis. Ocrelizumab treatment was associated with depletion of circulating B cells and CD20dim CD4+ and CD20dim CD8+ T cells (P < 0.0001, P = 0.0016, and P = 0.0008, respectively), but in CSF only with lower proportions of B cells and CD20dim memory CD4+ T cells (P < 0.0001 and P = 0.0043, respectively). The proportional prevalence of CSF CD20dim memory CD8+ T cells was not significantly reduced (P = 0.1333). Only in CSF, the proportions of CD20dim cells within CD4+ and not CD8+ T cells positive for CCR5, CCR6 and CXCR3 were reduced in ocrelizumab-treated participants. The proportion of CD20dim CD4+ T cells and abundance of CD4+ relative to CD8+ T cells in CSF correlated positively with age (R = 0.6799, P = 0.0150) and Age Related Multiple Sclerosis Severity Score (R = 0.8087, P = 0.0014), respectively. We conclude that, in contrast to CSF CD20dim CD8+ T cells, B cells and CD20dim CD4+ T cells are reduced in CSF of people with primary progressive multiple sclerosis with an ocrelizumab-associated depletion of circulating B cells and CD20dim T cells. Therefore, these cells are likely to contribute to the therapeutic effects of ocrelizumab in people with primary progressive multiple sclerosis.
- 28 December 2023
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 6 (1) , fcae021
Open AccessOcrelizumab associates with reduced cerebrospinal fluid B and CD20dim CD4+ T cells in primary progressive multiple sclerosis
The anti-CD20 monoclonal antibody ocrelizumab reduces disability progression in primary progressive multiple sclerosis. CD20 is a prototypical B cell marker, however subpopulations of CD4+ and CD8+ T cells in peripheral blood and cerebrospinal fluid (CSF) also express low levels of CD20 (CD20dim). Therefore, direct targeting and depletion of these CD20dim T-cell-subpopulations may contribute to the therapeutic effect of ocrelizumab. The aim of this observational cohort study was to compare CD20+ B cell and CD20dim T cell distributions between peripheral blood and CSF of ocrelizumab-treated or untreated people with primary progressive multiple sclerosis. Ocrelizumab treatment was associated with depletion of circulating B cells and CD20dim CD4+ and CD20dim CD8+ T cells (P < 0.0001, P = 0.0016, and P = 0.0008, respectively), but in CSF only with lower proportions of B cells and CD20dim memory CD4+ T cells (P < 0.0001 and P = 0.0043, respectively). The proportional prevalence of CSF CD20dim memory CD8+ T cells was not significantly reduced (P = 0.1333). Only in CSF, the proportions of CD20dim cells within CD4+ and not CD8+ T cells positive for CCR5, CCR6 and CXCR3 were reduced in ocrelizumab-treated participants. The proportion of CD20dim CD4+ T cells and abundance of CD4+ relative to CD8+ T cells in CSF correlated positively with age (R = 0.6799, P = 0.0150) and Age Related Multiple Sclerosis Severity Score (R = 0.8087, P = 0.0014), respectively. We conclude that, in contrast to CSF CD20dim CD8+ T cells, B cells and CD20dim CD4+ T cells are reduced in CSF of people with primary progressive multiple sclerosis with an ocrelizumab-associated depletion of circulating B cells and CD20dim T cells. Therefore, these cells are likely to contribute to the therapeutic effects of ocrelizumab in people with primary progressive multiple sclerosis.